Board of Directors
Company Risk
If errors or inaccuracies occur in laboratory testing or limitations arise in interpreting screening results, patients or physicians may rely on incorrect information for medical decision-making, which could potentially affect patients’ health. In addition, such incidents may undermine the confidence of patients, physicians, and business partners, and may adversely affect the Company’s image and reputation. In certain cases, they may also lead to complaints, claims for damages, or legal proceedings, which could impact the Company’s business operations and financial position.
To manage the aforementioned risks, the Company has established the following key measures: 1. Provision of Adequate Information and Informed Consent Prior to undergoing screening services, customers are provided with clear explanations regarding the objectives, limitations, and conditions of the tests, including factors that may affect the accuracy of the results. Such information is specified in the Consent Form to ensure that customers can make well-informed decisions. In addition, certain screening services may include a test result guarantee, under which customers may receive financial support for additional diagnostic testing if a high-risk result is detected, subject to the terms and conditions of the selected service package. 2. Quality Control and Standardized Testing Procedures The Company has established standardized operating procedures covering all stages of the laboratory process, by ISO15189:2022 and ISO15190:2020, from sample collection and preparation to analysis and reporting. The Company also utilizes standardized instruments, equipment, and reagents, and conducts regular calibration, maintenance, and both internal and external quality control to ensure the accuracy and reliability of test results. 3. Personnel Development and Service Quality Monitoring The Company places strong emphasis on enhancing the capabilities of its personnel by providing continuous training and development in relevant scientific knowledge and technologies. In addition, the Company regularly monitors and reviews service quality to effectively manage risks and maintain appropriate standards of service.
If the Company fails to comply with applicable laws, standards, or regulatory requirements, it may result in the suspension or cessation of its operations, revocation or suspension of its operating licenses, as well as fines or legal proceedings. In addition, the Company’s laboratory accreditation may be suspended or revoked, which could affect the reliability of test results and potentially cause damage to clients or organizations relying on such results. Non-compliance may also lead to accidents, contamination, or adverse impacts on the environment and the health and safety of laboratory personnel, as well as potential violations of clients’ personal data. Ultimately, these issues could adversely affect the Company’s reputation, credibility, and the confidence of customers and stakeholders in the long term.
The Company places importance on compliance with applicable laws, regulations, and requirements, and has established policies to manage risks related to legal and regulatory compliance as follows: 1. Governance and Monitoring of Legal and Regulatory Compliance The Company regularly monitors and reviews relevant laws, regulations, and requirements imposed by regulatory authorities. Changes in laws and regulations are monitored through various channels, such as official websites of relevant government agencies, participation in academic conferences, and professional associations. In addition, the risk management working group is assigned to periodically review relevant laws and regulatory requirements to ensure that the Company’s operations remain in compliance. 2. Quality Control and Laboratory Operational Standards The Company maintains quality control over its laboratory testing processes in accordance with relevant laboratory standards. This includes regular calibration and maintenance of equipment, as well as maintaining and reviewing quality management documentation to ensure the accuracy and reliability of laboratory test results. 3. Personnel Development, Safety Measures, and Data Protection The Company emphasizes enhancing personnel knowledge and understanding of operational procedures, regulations, and applicable laws. The Company also implements safety measures for laboratory operations and establishes measures to protect clients’ personal data, in order to support business operations in compliance with applicable laws and standards.
If the Company is unable to adapt effectively to increasing competition, technological changes, or fluctuations in the supply chain, it may result in a loss of market share, reduced competitiveness, or higher operating costs. In addition, shortages of laboratory equipment, instruments, or reagents used in testing may affect the continuity of the Company’s services. Furthermore, uncertainty in economic conditions may reduce demand for such services, which could adversely affect the Company’s revenue, operating performance, and growth prospects in the future.
To maintain its competitiveness and respond to changes in the industry, the Company has established the following risk management measures: 1. Continuous Development of Technology and Service Capabilities The Company closely monitors advancements in genomic medicine and laboratory testing technologies and continuously enhances its equipment, technologies, and service processes. Leveraging the innovations and technologies of the BGI Group, supported by one of the world’s largest genetic research databases, the Company is able to deliver accurate and reliable testing results. In addition, the Company performs laboratory testing within Thailand, which helps reduce turnaround time, lower transportation costs, and enhance flexibility in developing products and service packages that meet customer needs. 2. Strengthening Personnel Capabilities and Service Readiness The Company continuously develops the capabilities of its laboratory personnel and maintains standardized laboratory systems and equipment to support the rapid development and provision of new testing services. During the outbreaks of COVID-19 and Monkeypox Virus, the Company was able to promptly provide testing services after being approved as a network laboratory and successfully passing proficiency testing by the Department of Medical Sciences. The Company also maintains readiness to support testing services for emerging infectious diseases or new virus strains in the future.
If the Thai Baht (THB) depreciates against the U.S. dollar (USD), the cost of purchasing goods and equipment may increase, which could adversely affect the Company’s profit margins and operating results.
The Company closely monitors exchange rate trends and manages its purchasing and payment schedules in line with exchange rate conditions to mitigate potential impacts on its operations. In addition, the Company has a policy to utilize financial instruments for managing foreign exchange risk, such as entering into forward exchange contracts, and coordinates with financial institutions to obtain information and closely monitor exchange rate fluctuations on an ongoing basis.
If a data security incident occurs, it may result in the unauthorized disclosure or misuse of customer information, which could adversely affect customer confidence. The Company’s operations may be disrupted, and such incidents may also lead to financial losses, legal liabilities, and damage to the Company’s reputation and corporate image.
The Company has established comprehensive information security measures as follows: 1.Technical Measures The Company has implemented cybersecurity prevention and detection systems, such as a Next-Generation Firewall (NGFW), to monitor and protect against both external and internal threats in real time. In addition, the Company utilizes additional website protection services to restrict access to internal systems and mitigate cyberattack risks. 2.Policy and Procedural Measures The Company has established an Information Security Policy in accordance with international standards such as ISO 27001 and conducts regular IT risk assessments. Real-time alert systems are also in place to enable prompt response and mitigation of any abnormal incidents. 3.Personnel Measures The Company emphasizes the development of employees’ cybersecurity awareness by providing regular training programs. It also enhances specialized skills for IT personnel to strengthen readiness in preventing and responding to potential cyber threats.
Shareholder Risk
Compliance with securities laws or regulatory requirements in certain jurisdictions may result in some investors being unable to exercise their rights to subscribe for securities on a pro rata basis, which may lead to a dilution of their shareholding (Dilution Effect).
The Company carefully considers applicable legal and regulatory requirements in each jurisdiction when conducting securities offerings, and may appoint legal advisors or relevant experts to assess constraints and determine appropriate approaches. In addition, the Company will clearly and transparently disclose information regarding the terms and limitations of shareholders’ rights to enable investors to make informed decisions. The Company will also consider appropriate measures to mitigate potential impacts on shareholders within the scope permitted by applicable laws.
These factors may affect the Company’s competitiveness, operating costs, revenue, and overall performance, which could lead to volatility in the Company’s share price and result in investors receiving returns that may not meet their expectations.
The Company focuses on continuously developing its technology and service quality, alongside effective cost management and supply chain management. It also ensures strict compliance with relevant laws and standards, as well as accurate, transparent, and adequate disclosure of information to support investors in making informed decisions.
Unlock full benchmarking
Claim this company to see every KPI your sector qualifies for, from 70+ across the market, benchmarked against sector peers.
